Ricard Mesía

13PUBLICATIONS
80CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Toxicology (incl. clinical toxicology)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 08, 2026
Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy.

|Mar 13, 2025
Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes.

Patricia McCoon, Ying Wang, Zhongwu Lai

|May 23, 2024
Study of late toxicity biomarkers of locally advanced head and neck cancer patients treated with radiotherapy plus cisplatin or cetuximab points to the relevance of skin macrophages (TOX-TTCC-2015-01).

Antonio Rullan, Juan A Marín-Jiménez, Alicia Lozano

|Jul 27, 2023
Real-world treatment outcomes of medicines used in special situations (off-label and compassionate use) in oncology and hematology: A retrospective study from a comprehensive cancer institution.

Sandra Fontanals, Anna Esteve, Andrea González

|Mar 02, 2023
Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation.

Sophie Wildsmith, Jiabu Ye, April Franks

|Feb 22, 2023
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Sophie Wildsmith, Weimin Li, Song Wu

Pageof 3

Frequent Collaborators

3 joint publications

Lillian L Siu

3 joint publications

Irene Brana

2 joint publications

Barbara Burtness

2 joint publications

Richard Greil